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Abstract 
Introduction 
Using a randomized controlled trial comparing tight glucose control with a computerized 
decision-support systems and conventional protocols (post hoc analysis), we tested the 
hypothesis that hypoglycemia is associated with a poor outcome, even when controlling for 
initial severity. 
Methods 
We looked for moderate (2.2-3.3 mmol/l) and severe (<2.2 mmol/l) hypoglycemia, multiple 
hypoglycemic events (n ≥ 3), and the other main components of glycemic control (mean 
blood glucose level and blood glucose coefficient of variation (CV)). The primary end-point 
was 90-day mortality. We used both a multivariable analysis taking into account only 
variables observed at admission and a multivariable matching process (greedy matching 
algorithm, caliper width of 10
−5
 digit with no replacement). 
Results 
A total of 2,601 patients were analyzed and divided into three groups: no hypoglycemia (n = 
1,474), moderate hypoglycemia (n = 874, 34%), and severe hypoglycemia (n = 253, 10%). 
Patients with moderate or severe hypoglycemia had a poorer prognosis as shown by a higher 
mortality rate (36% and 54% respectively, vs. 28%) and decreased number of treatment-free 
days. In the multivariable analysis, severe (OR 1.50, 95% CI 1.36-1.56, P = 0.043) and 
multiple hypoglycemic events (OR 1.76, 95% CI 1.31-3.37, P < 0.001) were significantly 
associated with mortality whereas blood glucose CV was not. Using multivariable matching, 
patients with severe (53 vs. 35%, P < 0.001), moderate (33 vs. 27%, P = 0.029), and multiple 
hypoglycemic events (46 vs. 32%, P < 0.001), had a higher 90-day mortality. 
Conclusion 
In a large cohort of ICU patients, severe hypoglycemia and multiple hypoglycemic events 
were associated with increased 90-day mortality. 
Trial registration 
Clinicaltrials.gov Identifier NCT01002482 Registered 26 Octobrer 2009. 
Introduction 
Stress hyperglycemia and insulin resistance are frequent in critically ill patients and 
associated with poor outcome [1,2]. As compared to permissive hyperglycemia, intensive 
insulin therapy targeting a tight low range for blood glucose has been shown to reduce in-
hospital mortality in a single center randomized trial in critically ill surgical patients [3]. 
However, subsequent multicenter randomized controlled trials in broader intensive care unit 
(ICU) population did not find survival benefit [4-7] or suggested increased mortality [8]. In 
these studies a higher prevalence of hypoglycemia was associated with intensive insulin 
therapy. In diabetic patients, hypoglycemia is widely recognized as a severe adverse event, 
leading to neurological insult or death [9,10]. Such association is less clear in the ICU since 
some trials assessing tight blood glucose control observed an increased in hypoglycemia 
occurrence with [11,12] or without [4-7] significant increase in mortality. There is a clear 
association between severity of ICU patients and the occurrence of hypoglycemia [13] and 
this association may have been often underestimated when analyzing the possible link 
between hypoglycemia and mortality. Moreover, previous studies were associated with 
methodological concerns as they included events as covariates that may have been due to 
hypoglycemia [11,14], or because multivariate analyses may be subject of overfitting, 
because of the multiplicity of cofounders included in the model [15-17]. Therefore, the link 
between hypoglycemia and mortality remains a matter of debate, as well as its causality [18]. 
We used the large cohort of ICU patients included in our recent randomized study [7] to test 
the hypothesis that hypoglycemia is associated with a poor outcome, even when controlling 
for initial severity. For this purpose we used a multivariate analysis taking into account only 
variables observed at admission. We also used a multivariate matching process, which is less 
sensitive to unknown bias variables and is considered as more powerful, approaching the 
ideal randomization that is not possible here [19]. We also tested the two other main 
components of glycemic control (mean blood glucose level and blood glucose variability) 
that are suspected to be also linked to mortality in ICU patient [20]. 
Material and methods 
This is an ancillary study of the CGAO-REA trial (NCT01002482, Registered 26 
Octobrer2009), a non-blinded parallel-group randomized controlled trial involving adult 
patients admitted to ICUs and comparing tight glucose control with a clinical computerized 
decision-support systems (blood glucose range between 4.4 and 6.1 mmol/l) and conventional 
glucose control protocols (blood glucose levels inferior to 10 mmol/l), [7] and corresponds to 
a post hoc analysis. A subgroup analysis of patients with traumatic brain injury has also been 
published [21]. The study was approved by an ethical committee (Comité de Protection des 
Personnes, CCP de Tours, Tours, France). Written informed consent or delayed consent was 
obtained from each patient or a legal surrogate. 
Patients 
Adult patients who were assumed to require at least 3 days in the ICU were eligible for 
inclusion. We excluded moribund patients with imminent death or those for whom there were 
do-not-resuscitate orders or the attending physicians were not committed to full supportive 
care, patients admitted for treatment of diabetic ketoacidosis or hyperosmolar state, patients 
expected to be eating before the end of the day following the day of admission in the ICU, 
patients who had previously suffered hypoglycemia without documented full neurological 
recovery, and patients considered as being at high risk of suffering hypoglycemia. It was not 
mandatory that the patient experienced an episode of hyperglycemia within 24 hours after 
admission. 
Study design 
Within 24 hours after admission, patients were randomly assigned to undergo tight 
computerized glucose control or conventional blood glucose control [7]. Blood samples for 
glucose measurement were obtained by means of arterial catheters whenever possible; the use 
of capillary samples was discouraged. Blood glucose was measured with bedside glucose 
readers or preferentially with arterial blood gas analyzer devices when available. At least one 
blood glucose value per day was measured by the hospital central laboratory on a morning 
sample (morning laboratory blood glucose). Only the blood glucose values measured at the 
bedside (e.g. either with point-of-care glucose readers or with blood gas analyzers located in 
the ICU) were used uncorrected for the adaptation of insulin infusion rate. Each ICU used 
regular human insulin in saline with the same concentration (50 IU in 50 mL of 0.9% sodium 
chloride) with the use of a pump. A dedicated line for intravenous insulin infusion was 
encouraged to avoid occult administration of insulin or delay for effective application of a 
new insulin rate. Enteral feeding was attempted as early as possible. All other aspects of 
patient care, including nutritional management, were carried out at the discretion of the 
treating physicians. 
At baseline, clinical characteristics, including the Simplified Acute Physiology Score (SAPS 
II) [22], presence of trauma, the McCabe score for the evaluation of the prognosis of the 
underlying disease [23] and the Sequential Organ Failure (SOFA) [24] were collected. 
Definition of hypoglycemia and blood glucose metrics 
Blood glucose control was assessed by morning laboratory blood glucose each day until ICU 
discharge or day 28. Because different numbers of measures per day were obtained in the two 
groups, we extracted only 4 blood glucose measurements per day, closest to 2:00, 8:00, 
14:00, and 20:00, respectively. Severe hypoglycemia was defined as blood glucose < 2.2 
mmol/l and moderate hypoglycemia was defined as blood glucose between 2.2 and 3.3 
mmol/l, as previously described [7]. The number of hypoglycemic events was recorded in 
each patients and the density calculated (expressed as number of events per day of insulin 
administration and per day of ICU). We also recorded the mean, minimal, and maximal blood 
glucose readings during the intervention period, the standard deviation (SD) and coefficient 
of variation (CV) of blood glucose, and the total and daily doses of insulin. Blood glucose 
variability was considered as moderate (CV 0.20 to 0.39) or severe (CV >0.40) as previously 
described [16]. 
Outcome measures 
Study primary outcome was death from any cause within 90 days after ICU admission. 
Secondary predefined outcomes were death within 28 days after ICU admission, 28-day-ICU-
free days, 28-day-hospital-free days, 28-day-ventilator-free days (either mechanical 
ventilation or non-invasive ventilation), 28-day-free-of-catecholamines days, and 28-day-free 
of renal replacement therapy, as previously described [7,25]. These 28-day-free-of-treatment 
days were calculated by subtracting the actual treatment duration in days from 28, with 
patients who died at day 28 or before being assigned 0 free-days. We also compared the 
following main glucose metrics: mean blood glucose and blood glucose CV [20]. 
Statistical analysis 
Data are expressed as mean ± SD, median [25–75 interquartile], and number (percentage). 
Normality was assessed with the D’Agostino-Pearson omnibus test. Comparison of means 
was performed using the Student t test or analysis of variance and Newman-Keuls test, 
comparison of medians was performed using the Mann and Whitney test or Kruskall-Wallis 
test for multiple comparison, and comparison of proportions was performed using Fisher’s 
exact method with Bonferroni correction when appropriate. Using logistic regression and 
using all variables known at admission in ICU, we determined variables associated with 
mortality at 90 days and calculated odds ratios (OR) and their 95% confidence interval (CI). 
Co-linearity between variables was considered when r > 0.60 (Spearman coefficient matrix 
correlation). Calibration of the model was assessed using the Hosmer-Lemeshow test, and 
discrimination using the c-statistic. This model enables us to calculate the probability of death 
at 90 days. Then we conducted a multivariate analysis including all significant variables in 
the model (age, BMI, SAPS II score, SOFA score, McCabe score, and the cause of ICU 
admission) and by forcing the main variables of blood glucose metrics: severe and moderate 
hypoglycemia, number of hypoglycemic events (any type, 0 to 2 vs. ≥ 3), mean blood glucose 
level, blood glucose CV, and type of blood glucose control conventional vs. computerized) in 
the model. 
To reduce the effects of confounding, matched populations of patients without hypoglycemia 
and patients with moderate or severe hypoglycemia were created using propensity score 
matching. The propensity model was constructed to match pairs of patients without 
hypoglycemia and hypoglycemic patients using a multivariable logistic model and a greedy 
matching algorithm with a 1:1 (moderate hypoglycemia) or 2:1 (severe hypoglycemia, 
multiple hypoglycemic events) ratio and a caliper width of 10
−5
 digit with no replacement. 
Propensity score matching is one of the propensity score methods used to mimic some of the 
characteristics of a randomized controlled trial [26]. Applied to the context of our 
observational study on hypoglycemic events, it consists in forming matched sets of 
hypoglycemic and non-hypoglycemic patients who share a similar value of the propensity 
score. In greedy matching within a specified caliper distance, a hypoglycemic patient is first 
selected at random; the patient without hypoglycemia whose propensity score is closest to 
that of this randomly selected hypoglycemic patient (with the further restriction that the 
absolute difference in the propensity scores of matched patients must be below the caliper 
distance) is chosen for matching to this hypoglycemic patient. This process is called greedy 
because at each step in the process, the nearest patient without hypoglycemia is selected for 
matching to the given hypoglycemic patient, even if that patient without hypoglycemia would 
better serve as a match for a subsequent hypoglycemic patient. This nearest patient without 
hypoglycemia is no longer available for a new match with another hypoglycemic patient (no 
replacement). If no patients without hypoglycemia had propensity scores that lay within the 
specified caliper distance of the propensity score of the hypoglycemic patient, this unmatched 
hypoglycemic patient would then be excluded from the matching process. All variables 
available at admission were included in the matching model. Patients without hypoglycemia 
and hypoglycemic patients, for whom no paired match was found, were discarded from the 
analysis. After matching, absolute standardized differences (ASD) were calculated to assess 
the similarity in pre-operative patient characteristics, and expressed as a percentage. An ASD 
above 10% was considered to represent meaningful difference [27]. In order to estimate the 
association of hypoglycemia and mortality in population predefined subgroups, the same 
analysis was then conducted in diabetic and non-diabetic patients, and in the two groups 
(conventional vs. computerized blood glucose control). 
All P values were two-tailed and a P value of less than 0.05 was considered significant. 
Statistical analysis was performed using NCSS 7.0 software (Statistical solutions Ltd., Cork, 
Ireland) and R 3.1.1 software (www.cran.r-project.org, last date accessed August 9, 2014). 
Results 
Among the 2,684 randomized patients, 1,351 were assigned to computerized and 1,333 to 
conventional blood glucose control. Thirty-six patients were discarded from any analysis (35 
withdrew consent and 1 was included twice). Among the 2,648 remaining patients, 47 were 
discarded because important data concerning blood glucose measurement were lacking. Thus, 
2,601 patients were analyzed (Figure 1). 
Figure 1 Flow chart of the study. 
Hypoglycemia (<3.3 mmol/l) occurred in 1127 (43%, 95% CI 41-45%) patients. The density 
of hypoglycemia was 0.30 events per day of insulin therapy and 0.15 events per day in the 
ICU. Severe hypoglycemia (<2.2 mmol/l) occurred in 253 (10%, 95% CI 9-11%) patients. 
The density of severe hypoglycemia was 0.037 events per day of insulin therapy and 0.020 
events per day in the ICU. Moderate hypoglycemia (2.2 to 3.3 mmol/l) occurred in 874 (34%, 
95% CI 32-35%) patients. The density of moderate hypoglycemia was 0.26 events per day of 
insulin therapy and 0.13 events per day in the ICU. Figure 2 shows the distribution of the 
number of hypoglycemic events (severe, moderate, any type) per patient. Multiple 
hypoglycemic events (any type, n ≥ 3) occurred in 482 (19%, 95% CI 17-20%) patients and 
their 90-day mortality was significantly increased as compared to patients with less 
hypoglycemic events (51 vs. 29 %, P < 0.001). Blood glucose variability was available in 
2,507 patients. Moderate blood glucose variability (CV 0.20 to 0.39) occurred in 1,447 (56%, 
95% CI 54-58%) patients, and severe blood glucose variability (CV ≥0.40) occurred in 238 
(9%, 95% CI 8-10%) patients. The 90-day mortality was higher in patients with moderate or 
severe blood glucose variability as compared to controls (36 vs. 24%, P < 0.001; 42 vs. 24%, 
P < 0.001, respectively). There was no significant difference in 90-day mortality between 
moderate and severe blood glucose variability (P = 0.21). 
Figure 2 Distribution of the number of hypoglycemic events (A: severe (<2.2 mmol/l) B: 
moderate (2.2 to 3.3 mmol/l); C: any type (<3.3 mmol/l) per patient. 
Patients were divided into three groups: No hypoglycemia (n = 1,474), Moderate 
hypoglycemia (n = 874), and Severe hypoglycemia (n = 253) (Figure 1). The main 
characteristics of patients in these 3 groups are shown in Table 1. Patients with moderate or 
severe hypoglycemia had worse outcome (Table 1). However, they had more severe illness as 
shown by higher SAPS II and SOFA scores. They had more underlying diabetes, were more 
frequently mechanically ventilated, on vasopressor therapy, or on renal replacement therapy 
(Table 1). Blood glucose data are shown in Table 2. Patients with moderate or severe 
hypoglycemia had higher blood glucose variability (SD and CV) and lower mean blood 
glucose levels (Table 2). Comparable results were noted when considering patients with 
multiple hypoglycemic events (Table 1). 
Table 1 Baseline characteristics and outcome of the study patients 
Variables No hypoglycemia 
(n = 1,474) 
Moderate 
hypoglycemia 
(n = 874) 
Severe hypoglycemia 
(n = 253) 
Multiple 
hypoglycemic 
events 
(n = 482) 
Age, yr 61 (17) 63 (16) 62 (15) 63 (15) 
Male sex, n (%) 963/1,474 (65) 553/874 (63) 163/253 (64) 320/482 (65) 
Weight, kg 80 (21) 75 (18)* 74 (20)* 74 (18)* 
Body mass index, kg.m−2 27.5 (6.7) 26.2 (5.9)* 25.6 (6.1)* 25.9 (6.0) 
SAPS II score 46 [34–61] 52 [40–67]* 59 [46–74]*† 65 [55–75]* 
SOFA score 7 [4–10] 8 [5–11]* 10 [7–13] *† 10 [7–12]* 
McCabe score 1 [1–2] 1 [1–2] 1 [1–2] 1 [1–2] 
Type of patients     
     Medical 872/1,474 (59) 161/874 (60) 161/253 (64) 281/482 (60) 
     Scheduled surgical 457/1,474 (31) 75/874 (29) 75/253 (30) 158/482 (30) 
     Emergency surgical 145/1,474 (10) 17/874 (11) 17/253 (7) 53/482 (10) 
History of diabetes mellitus, n (%) 266/1,474 (18) 189/874 (22) 70/253 (28)* 131/482 (27) 
     Type 1 diabetes, n (%) 38/1,474 (3) 32/874 (4) 14/253 (6) 22/481 (5) 
     Type 2 diabetes, n (%) 228/1,474 (15) 157/874 (18) 55/253 (22) 108/481 (22) 
     Nor determined     
Previous treatment 118/1,474 (5) 21/873 (8) 21/253 (8) 35/482 (7) 
     Insuline, n (%) 114/1,474 (5) 18/873 (7) 18/253 (7) 28/482 (6) 
     Antidiabetic drugs, n (%)     
Plasma creatinine, μmol.L−1 133 (140) 150 (133) 166 (158)* 169 (147)* 
Initial treatment in the ICU     
     Mechanical ventilation 1,273/1,430 (89) 803/873 (92) 240/253 (95)* 453/482 (94)* 
     Catecholamines 708/1,428 (50) 533/253 (61)* 195/253 (77) *† 353/482 (73) 
     Renal replacement therapy 119/1,428 (8) 123/253 (14)* 54/253 (21) *† 96/482 (20)* 
     Antibiotics 924/1,428 (65) 597/253 (68) 180/253 (71) 351/482 (73) 
Blood glucose control     
     Conventional 900/1,474 (61) 305/874 (35)* 79/253 (31)* 126/482 (26)* 
     Computerized 574/1,474 (39) 569/874 (65)* 174/253 (69)* 356/482 (74)* 
Treatment-free days     
     Mechanical ventilation 21 [0–26] 14 [0–23]* 0 [0–18] *† 1 [0–18]* 
     Catecholamines 26 [17–28] 23 [0–27]* 15 [0–24] *† 18 [0–25]* 
     Renal replacement therapy 28 [21–28] 28 [0–28]* 15 [0–28] *† 24 [0–28]* 
ICU-free days 20 [0–25] 12 [0–12]* 0 [0–17] *† 0 [0–117]* 
Mortality     
     Day 28 315/1,474 (21) 222/874 (25) * 100/253 (39) *† 162/482 (34)* 
     Day 90 407/1,474 (28) 315/874 (36)* 137/253 (54) *† 248/482 (51)* 
Data are expressed as mean (SD), median [25–75 interquartile], and No. (%). 
ICU = Intensive care unit; SAPS II = Simplified Acute Physiology Score II, scores can range from 0 to 156 with higher 
scores indicating more severe illness; SOFA = can range from 0 to 24 with higher scores indicating more severe illness; 
*: P < 0.05 vs No hypoglycemia group; †:P < 0.05 vs Moderate hypoglycemia group (comparison was performed only for 
Severe hypoglycemia group). 
Table 2 Blood glucose metrics 
Variables No hypoglycemia 
(n = 1,474) 
Moderate 
hypoglycemia 
(n = 874) 
Severe hypoglycemia 
(n = 253) 
Multiple hypoglycemic 
events 
(n = 482) 
Initial blood glucose, mmol.L−1 8.9 (4.0) 9.6 (4.6)* 9.8 (5.5)* 9.7 (4.2)* 
Mean morning blood glucose, mmol.L−1 7.2 (2.3) 6.8 (1.6)* 6.8 (1.8)* 6.7 (1.8)* 
Mean blood glucose, mmol.L−1 7.2 (1.7) 6.7 (1.2)* 6.8 (1.5)* 6.6 (1.2)* 
Maximum blood glucose, mmol.L−1 11.3 (1.4) 12.8 (4.1)* 14.6 (5.1)*† 14.2 (4.9)* 
Minimum Blood glucose, mmol.L−1 4.6 (1.4) 2.9 (0.3) 1.7 (0.4) 2.2 (0.6) 
Blood glucose SD, mmol.L−1 1.5 (1.0) 2.0 (1.0)* 2.4 (1.3)*† 2.2 (1.1)* 
Blood glucose CV 0.20 [0.15-0.26] 0.27 [0.22-0.34]* 0.32 [0.25-0.39]*† 0.31 [0.25-0.38]* 
Blood glucose CV >0.20 715/1428 (50%) 735/873 (84%)* 235/253 (93%)*† 452/479 (94%)* 
Total insulin dose (IU) 121 [38–344] 348 [123–801]* 442 [129–986]* 534 [201–1109]* 
Daily insulin dose (IU.day−1) 19 [4–41] 34 [15–58]* 35 [17–59]* 38 [20–61]* 
Day with insulin 5 [3–11] 9 [4–17]* 10 [5–20] *† 12 [6–22] * 
Number of blood glucose measurements 28 [16–56] 44 [24–80]* 52 [28–104]*† 50 [32–108]* 
Number of moderate hypoglycemia   3 [1–6] 4 [3–6] 
Number of severe hypoglycemia - 2 [1–3] 1 [1–2] 0 [0–1] 
Number of hypoglycemic events (any type) - - 5 [3–8] 4 [3–7] 
Hypoglycemic events (any type) ≥3 - 2 [1–3] 197 (77%) 482 (100%) 
286 (33%)   
Data are expressed as mean (SD), median [25–75 interquartile], and No. (%). CV: coefficient of variation. 
*: P < 0.05 vs No hypoglycemia group; †:P < 0.05 vs Moderate hypoglycemia group (only for Severe hypoglycemia group). 
The number of hypoglycemic events and the minimum blood glucose were not tested for statistical significance. 
In the multivariable model, 6 variables were significantly associated with 90-day mortality: 
age, BMI, SAPS II score, SOFA score, McCabe score, and the cause of ICU admission. The 
discrimination of the model was appropriate (c-statistic 0.745) as well as its calibration 
(Hosmer-Lemeshow test, Chi2 = 10.12, P = 0.34). When added to this model, severe 
hypoglycemia, multiple hypoglycemic events, and mean blood glucose level variables were 
significantly associated with 90-day mortality in contrast to moderate hypoglycemia and 
blood glucose CV (Table 3). We performed then a sensitivity analysis by excluding patients 
allocated to computerized blood glucose control and the variables severe hypoglycemia (OR 
2.08 95% CI 1.12-3.86, P = 0.02) and mean blood glucose level (OR 1.10, 95% CI 1.00-1.21, 
P = 0.045) remained significantly associated with 90-day mortality whereas the variables 
moderate hypoglycemia (OR 134, 95% CI 0.94-1.91, P = 0.11) and multiple hypoglycemic 
events (OR 1.42, 95% CI 0.85-2.37, P = 0.18) were not. 
Table 3 Multivariable analysis of variables associated with 90-day mortality (n = 2,312) 
Variables Odds ratio [95% IC] P value 
Age (per 1 year) 1.024 [1.017-1.031] <0.001 
Body mass index (per 1 kg.m−2) 0.979 [0.963-0.995] 0.008 
SAPS II score (per 1 point) 1.019 [1.012-1.025] <0.001 
SOFA score (per 1 point) 1.086 [1.053-1.120] <0.001 
McCabe score (per 1 point) 1.587 [1.357-1.885] <0.001 
Type of patient   
     Medical 1 - 
     Scheduled surgical 0.663 [0.532-0.827] <0.001 
     Emergency surgical 0.460 [0.321- 0.657] <0.001 
Moderate hypoglycemia 1.114 [0.865-1.436] 0.40 
Severe hypoglycemia 1.571 [1.055-2.339] 0.03 
Number of hypoglycemic events ≥3 1.834 [1.361-2.471] <0.001 
Mean blood glucose (per 1 mmol.L−1) 1.086 [1.010-1.168] 0.03 
Blood glucose CV <0.20 1 - 
Blood glucose CV 0.20-0.39 1.155 [0.906-1.472] 0.24 
Blood glucose CV ≥0.40 1.041 [0.698-1.552] 0.84 
Computerized blood glucose control 0.786 [0.639-0.958] 0.02 
CV: coefficient of variation; OR: odds ratio; CI: confidence interval; c-index: 0.757. 
Using multivariable matching, we matched each patient with severe hypoglycemia with 2 
patients without hypoglycemia, each patient with moderate hypoglycemia with 1 patient 
without hypoglycemia, and each patient with multiple hypoglycemic events with 2 patients 
without hypoglycemia. The proportion of discarded patients were 27% in the moderate 
hypoglycemia group, 21% in the severe hypoglycemia and 51% in the multiple hypoglycemic 
events groups. After matching the highest ASD was 5.9%. Table 4 shows the comparison 
between these matched groups of patients. Although the matching process provided two 
groups that were comparable for severity, patients with moderate or severe hypoglycemia and 
those with multiple hypoglycemic events had a poorer prognosis as shown by a higher 90-day 
mortality and decreased number of treatment-free days (Table 4). 
Table 4 Comparison of outcome and blood glucose metrics in matched groups 
 Matching for moderate hypoglycemia Matching for severe hypoglycemia 
Variables No hypoglycemia 
(n = 640) 
Moderate hypoglycemia 
(n = 640) 
P value No hypoglycemia 
(n = 366) 
Severe 
hypoglycemia 
(n = 199) 
P value 
Probability of death 0.28 (0.19) 0.28 (0.18) 0.66 0.32 (0.19) 0.35 (0.19) 0.12 
Outcome       
RRT free days 28 [21–28] 28 [7–28] 0.06 28 [0–28] 24 [0–28] <0.001 
Catecholamines free days 25 [17–27] 24 [2–27] <0.001 24 [0–26] 18 [0–25] <0.001 
Mechanical ventilation free days 20 [0–25] 15 [0–23] <0.001 17 [0–24] 18 [0–25] <0.001 
ICU free days 19 [0–24] 13 [0–22] <0.001 17 [0–24] 0 [0–28] <0.001 
Mortality 28 days 137 (21%) 151 (24%) 0.38 102 (28%) 75 (38%) 0.017 
Mortality 90 days 176 (27%) 213 (33%) 0.029 131 (35%) 106 (53%) <0.001 
Blood glucose metrics       
Mean blood glucose 7.2 (1.6) 6.6 (1.1) <0.001 7.3 (1.6) 6.8 (1.5) <0.001 
Blood glucose CV 0.21 (0.09) 0.28 (0.09) <0.001 0.22 (0.09) 0.33 (0.12) <0.001 
Insulin dose (IU.day−1) 22 [6–43] 35 [5–59] <0.001 23 [7–41] 35 [19–56] <0.001 
 Matching for multiple hypoglycemic events    
Variables No hypoglycemia 
(n = 445) 
Multiple hypoglycemic 
(n = 234) 
P value    
Probability of death 0.32 (0.20) 0.32 (0.19) 0.81    
Outcome       
RRT free days 28 [0–28] 28 [0–28] 0.06    
Catecholamines free days 24 [0–26] 19 [0–25] 0.001    
Mechanical ventilation free days 18 [0–24] 5 [0–18] <0.001    
ICU free days 17 [0–24] 1 [0–17] <0.001    
Mortality 28 days 115 (26%) 64 (27%) 0.71    
Mortality 90 days 141 (32%) 108 (46%) <0.001    
Blood glucose metrics       
Mean blood glucose 7.0 (1.5) 6.7 (1.0) <0.001    
Blood glucose CV 0.24 (0.10) 0.31 (0.09) <0.001    
Insuline dose (IU.day−1) 26 [8–49] 41 [22–63] <0.001    
Data are expressed as mean (SD), median [25–75 interquartile], and No. (%). 
ICU = intensive care unit; RRT: renal replacement therapy; CV = coefficient of variation. 
The association of severe and moderate hypoglycemia, and multiple hypoglycemic events 
with 90-day mortality was not different among the pre-specified subgroup analyses (non-
diabetic patients, computerized decision-support systems and conventional glucose control), 
except for diabetic patients (Figure 3). 
Figure 3 Sub group analysis. Odds ratio (OR) and 95% confidence interval (CI) for death at 
90 days associated with moderate (full square) or severe (full circle) hypoglycemia or 
multiple (n ≥ 3) hypoglycemic (full triangle) events in total population and in matched 
subgroups according to treatment assignment (conventional vs. computerized decision 
support system, CDSS) and diabetic status (diabetic vs. non diabetic). Matching was 
performed using propensity score and a ratio of 2:1 for severe hypoglycemia and 1:1 for 
moderate hypoglycemia and multiple hypoglycemic events. The size of symbols is related to 
the number of patients (N) retained in the matching process. 
Discussion 
In this study, in a large cohort of ICU patients and using two different statistical approaches, 
we observed that both severe hypoglycemia and multiple hypoglycemic events were 
associated with increased risk of death. Blood glucose CV was not associated with mortality. 
From a methodological and clinical point of view, we considered that it was important to 
perform the best possible adjustment for severity but using only variables observed at ICU 
admission. In contrast to some previous studies [11,28], we avoided to include any post ICU 
admission variable, such as the ICU length of stay because, if hypoglycemia has intrinsic 
deleterious effects, it should have been able to also impact these variables. We observed 
indeed that hypoglycemia was associated with increased ICU length of stay and use of 
mechanical ventilation, catecholamines, and renal replacement therapy, even when adjusting 
for initial severity (Tables 3 and 4). Although many studies found an association between 
hypoglycemia and mortality [11-17,28], others did not [14,29]. Using two different statistical 
approaches, our study confirms this association between hypoglycemia and mortality, at least 
when considering patients with severe hypoglycemia and multiple hypoglycemic events 
(Tables 3 and 4). Matching using propensity score is increasingly used in the medical 
literature [30] and has been shown to perform better than multivariable logistic regression in 
many situations [19]. In our study, these two approaches lead to consistent estimates of 
increased 90-day mortality associated with hypoglycemia. The magnitude of the increased 
risk of death observed in our study is also consistent with those previously reported 
[11,16,17,25,31]. 
There are three recognized domains of blood glucose metrics, mean blood glucose level, 
hypoglycemia, and blood glucose variability and all of them have been suspected to be linked 
to mortality in critically ill patients [13,20]. An important difficulty arises because all these 
variables are associated with initial severity in ICU patients and are significantly correlated 
one with the other, mathematically and probably clinically. Moreover, diabetic status is 
thought to modulate these relations [28] and the dose of insulin may also be considered as a 
fourth domain since a high dose of insulin may indicate a high degree of insulin resistance 
(which is also linked to illness severity) [32] and/or may be associated with non-glucose 
related therapeutic effects of insulin [33]. Consequently, there is some debate concerning the 
respective role of the different main domains of blood glucose metrics. Our study provides 
some evidence that blood glucose variability is less important than hypoglycemia. First, we 
did not observe a dose–response relationship for 90-day mortality with CV, using either a 
crude or adjusted analysis. Second, after adjusting for initial severity, blood glucose CV was 
not significantly associated with mortality (Table 3). 
Although we performed the best adjustment possible using variables associated with initial 
severity, a causal relationship between hypoglycemia and mortality cannot be proven in such 
an observational study [34]. Nevertheless, some arguments are in favor of the existence of a 
causal relationship in an observational study, at least partially [35]. Among them (strength 
and consistency of the association, specificity, temporal relationship, plausibility, coherence, 
experiment, analogy), the NICE-SUGAR investigators have already evidenced specificity 
since the association was strongest for death from distributive shock [13]. As previously 
observed [11,13,14,17,28,31], we observed a dose–response relationship as severe 
hypoglycemia was associated with higher rates of death than was moderate hypoglycemia or 
the occurrence of multiple hypoglycemic events. The fact that blood glucose variability did 
not seem to be associated with mortality is an important point, which reinforces the 
hypothesis that hypoglycemia (at least severe and/or multiple) is deleterious. It may be also 
an argument against the hypothesis that the harm of hypoglycemia comes instead from its 
rapid correction leading to rebound hyperglycemia [13] because this situation is expected to 
increase blood glucose variability. As previously reported [28], our study also confirms that 
diabetic patients may behave differently (Figure 3) but the small sample size of this group 
precludes definite conclusion. 
Our study may enable us to reanalyze our previous published trial on tight blood glucose 
control which was characterized by a significant decrease in mean blood glucose with a 
significant increase in hypoglycemia rate without any impact on mortality [7]. It should be 
pointed out that such discrepancy between mortality rate (unchanged) and hypoglycemia rate 
(increased) was also observed in all previous major trials [4-6] except one [8], excluding the 
first trial performed during an era without any blood glucose control performed in the control 
group [3]. This discrepancy was also confirmed by the more recent meta-analysis [36]. 
Considering that hypoglycemia may be both a marker of severity and a deleterious event, two 
different hypotheses can be evoked in our trial [7]. First, the benefit of the improvement in 
blood glucose control may have been masked by the deleterious effects of hypoglycemia. 
Second, if hypoglycemia is only a marker of illness severity, tight blood glucose may have 
induced iatrogenic hypoglycemia, which may not be associated with higher mortality rate. It 
is not possible to draw definite conclusion and the two hypotheses may not be exclusive. 
Anyway, since many arguments suggest that hypoglycemia, at least severe and/or multiple 
ones, may be, at least partially, causally associated with mortality, clinicians and caregivers 
should continue to avoid, detect, and treat hypoglycemia, particularly when severe and/or 
repeated. It should be pointed out that we were not able to differentiate iatrogenic (related to 
insulin administration) and spontaneous hypoglycemic events whereas the last one is thought 
to be more strongly associated with mortality but with possible less causality link [37]. Our 
study provides additional arguments to reduce or suppress hypoglycemic events induced by 
insulin protocols. Indeed, although most recommendations or guidelines have recently 
advocated for a higher glucose range target in the ICU based on recent meta-analyses 
showing a strong association between the glucose range targeted in insulin protocols and the 
risk for hypoglycemia, our study should lead to optimization the quality of glycemic control 
by improving the algorithms embedded in glucose controllers that calculate insulin rates to 
avoid hypoglycemia, especially in situations where the patient is exposed to variable insulin 
resistance, rather than by simply increasing the blood glucose target. In other words, 
minimizing occurrence and recurrence of hypoglycemic events seems more clinically 
relevant than choosing a high blood glucose target. It has already been demonstrated that an 
advanced protocol may both decrease the average blood glucose level and reduce the 
incidence of hypoglycemic events [38]. Further studies will be required to develop the high-
performance glucose controllers in the ICU and to determine the best compromise between 
individualized blood glucose targets and the risk of hypoglycemia. Finally, whatever the 
causal link between hypoglycemia and mortality, prevention of hypoglycemic events is 
needed in the ICU because the occurrence of severe hypoglycemia is a priori associated with 
an increase in nurse workload (via additional time required for administering glucose in cases 
of severe hypoglycemia, wich then subsenquently increases the risk of hyperglycemic 
rebound and creates a need for more frequent blood glucose monitoring after the 
hypoglycemic event [in the absence of continuous blood glucose monitoring system]). 
In the same manner, our database did not enable us to assess the attributable mortality by 
incorporating the evolution in severity of illness during the ICU stay and using causal 
inference methods [39]. 
The strengths of our study are its size, its prospective and multicentric nature with a high 
proportion of patients treated with insulin (98%), a low mean blood glucose level (7.2 
mmol/l) within the actual recommended target [40], and a high proportion of patients still in 
the ICU on the third day (94%). The initial high severity of our patients is shown by the high 
severity scores (median SAPS2 51, median SOFA 8) and the high mortality rate (33%) [7]. 
Our study has several limitations. First, sampling of blood glucose was intermittent and thus 
it is possible that some patients had undetected hypoglycemia. Second, another limitation is 
the absence of data regarding nutritional intakes. Third, the fact that our cohort comprises two 
randomized groups with different methods of blood control may also be considered as a 
limitation. Nevertheless, the use of a computerized decision support system seemed not to 
have interfered with our results, except for the role of moderate hypoglycemia since the 
association between moderate hypoglycemia and mortality was different between the two 
randomized groups (Figure 3). Fourth, the diabetic status of our patients was not precisely 
determined using measurement of blood glucose after provoked hyperglycemia or glycated 
hemoglobin measurement and thus we did not identify patients with prediabetic or occult 
diabetic status. In ICU patients, hyperglycemia seems to be not associated with significant 
increase in mortality in the subgroup of patients with premorbid hyperglycemia [41] but 
information is lacking considering hypoglycemia. Fifth, in ICU patients, severity of 
hypoglycemic events is usually defined by a biological threshold without possibility to 
precisely record clinical signs and this should also be considered as a limitation, as well as 
the lack of recording of the duration of the hypoglycemic events and the possible associated 
rebound in blood glucose levels. Sixth, we did not test all possible metrics of blood glucose 
variability but no significant difference has been shown between them [20]. Lastly, since we 
included only adult patients, our results may not apply to a pediatric population [42]. 
Conclusion 
In a large cohort of ICU patients, and using two different but concordant statistical 
approaches, we observed that severe hypoglycemia and multiple hypoglycemic events were 
associated with increased risk of death at 90 days. In contrast, blood glucose variability was 
not associated with 90-day mortality. 
Key messages 
• Severe hypoglycemia (<2.2 mmoml/l) is associated with increased risk of death at 90 days 
in critically ill patients 
• Multiple hypoglycemic episodes (at least 3 of any type of hypoglycemia, severe or 
moderate [2.2 to 3.3 mmol/l]) are associated with increased risk of death at 90 days in 
critically ill patients 
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